Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting
暂无分享,去创建一个
A. Sieuwerts | D. Lambrechts | P. V. van Dam | D. Peeters | G. G. Van den Eynden | P. Pauwels | P. Vermeulen | L. Dirix | S. V. van Laere | F. Rothé | P B Vermeulen | L Y Dirix | F Rothé | D Lambrechts | S J Van Laere | A. Rutten | A. Sieuwerts | P A van Dam | A M Sieuwerts | D J E Peeters | B De Laere | G G Van den Eynden | M Ignatiadis | A Rutten | P Pauwels | M Peeters | M. Peeters | B. De Laere | B. D. Laere | M. Ignatiadis | Peter B. Vermeulen | G. V. D. Eynden | S. V. Laere | P. A. V. Dam | Françoise Rothé | Diether Lambrechts | Patrick Pauwels | Marc Peeters | P. V. Dam
[1] J. Cooper,et al. Tumors on chips: oncology meets microfluidics. , 2010, Current opinion in chemical biology.
[2] D. Kerr,et al. Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.
[3] John A. Foekens,et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR , 2009, Breast Cancer Research and Treatment.
[4] John W M Martens,et al. mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients , 2011, Clinical Cancer Research.
[5] D. Dearnaley,et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. , 2009, Cancer research.
[6] Mieke Schutte,et al. Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells , 2009, Journal of the National Cancer Institute.
[7] Brigitte Rack,et al. Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.
[8] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[9] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[10] P. D. Rijk,et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing , 2011, Nature Biotechnology.
[11] J. Thiery,et al. Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer , 2007, Clinical & Experimental Metastasis.
[12] Michael Morse,et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Mehmet Toner,et al. Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.
[14] S. Kurtz,et al. Quantitative High-Resolution Genomic Analysis of Single Cancer Cells , 2011, PloS one.
[15] Gyan Bhanot,et al. Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines , 2012, PloS one.
[16] Roberto Guerrieri,et al. Electronic sorting and recovery of single live cells from microlitre sized samples. , 2006, Lab on a chip.
[17] V. Valero,et al. Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer , 2012, Molecular Cancer Therapeutics.
[18] William Pao,et al. Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus , 2007, Clinical Cancer Research.
[19] Jun Liu,et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Joe W. Gray,et al. What are we learning from the cancer genome? , 2012, Nature Reviews Clinical Oncology.
[21] J. Geigl,et al. Combined molecular genetic and cytogenetic analysis from single cells after isothermal whole-genome amplification. , 2011, Clinical chemistry.
[22] M. Fukuoka,et al. Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] K. Polyak,et al. Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.
[24] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[25] N. Stoecklein,et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer , 2002, The Lancet.
[26] K. Pienta,et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.
[27] Thierry Voet,et al. New Array Approaches to Explore Single Cells Genomes , 2011, Front. Gene..
[28] Sridhar Ramaswamy,et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signaling in metastasis , 2012, Nature.
[29] K. Sermon,et al. PGD for monogenic disorders: aspects of molecular biology , 2009, Prenatal diagnosis.
[30] L. Pusztai,et al. Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.
[31] Mark Clemons,et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Ben H. Park,et al. Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood , 2012, Clinical Cancer Research.
[33] Johannes G. Reiter,et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.
[34] A. Puisieux,et al. Metastasis: a question of life or death , 2006, Nature Reviews Cancer.
[35] T. Saida,et al. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level , 2012, British Journal of Cancer.
[36] J. Thiery,et al. Real‐time quantitative PCR determination of urokinase‐type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients , 2005, International journal of cancer.
[37] Enzo Medico,et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.
[38] C. Sotiriou,et al. HER2-Positive Circulating Tumor Cells in Breast Cancer , 2011, PloS one.